Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of AMGN have gained 13.5%, while those of BMY have gained 13.9%. The industry has ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: ...

Bridgewater headquartered Amneal Pharmaceuticals Inc, a global biopharmaceutical company, and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, announced that ...

The listed company informed the PSX that Arshad Anis has been appointed as the chairman of the company with effect from today ...

Analysts are forecasting that Injective (INJ) could reach $4.90 by 2030. Feeling confident about this Injective price prediction? You can trade Injective on Coinbase—and if you're new to the platform, ...

Amneal Pharmaceuticals and mAbxience received Food and Drug Administration approval for two biosimilars. The companies said Monday that the FDA greenlit Biologics Licensing Applications for Boncresa, ...

Ellen and Tanya have both lost weight using GLP-1s but have had very different experiences when it comes to stopping the medication "It's like a switch that goes on and you're instantly starving." ...